These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1325955)

  • 21. Effect of suramin on growth of androgen-responsive mouse tumor (Shionogi carcinoma 115) and its autonomous subline (Chiba subline 2).
    Furuya Y; Sato N; Watabe Y; Shimazaki J
    Endocrinol Jpn; 1990 Dec; 37(6):933-42. PubMed ID: 1966284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells.
    Hinek A; Jung S; Rutka JT
    Acta Neuropathol; 1999 Apr; 97(4):399-407. PubMed ID: 10208280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M; van den Berg HW; Lynch M
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of receptors for recombinant human tumor necrosis factor-alpha from human placental membranes.
    Aiyer RA; Aggarwal BB
    Lymphokine Res; 1990; 9(3):333-44. PubMed ID: 2169011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells.
    Pollak M; Richard M
    J Natl Cancer Inst; 1990 Aug; 82(16):1349-52. PubMed ID: 2166171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of tumor necrosis factor receptors in tumor necrosis factor-alpha-mediated cytolysis of ovarian cancer cell lines.
    Kost ER; Herzog TJ; Adler LM; Williams S; Mutch DG
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):145-53. PubMed ID: 8571998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.
    Minniti CP; Maggi M; Helman LJ
    Cancer Res; 1992 Apr; 52(7):1830-5. PubMed ID: 1312901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suramin inhibits beta-bungarotoxin-induced activation of N-methyl-D-aspartate receptors and cytotoxicity in primary neurons.
    Tseng WP; Lin-Shiau SY
    Toxicol Appl Pharmacol; 2003 May; 189(1):45-55. PubMed ID: 12758059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression.
    Mills GB; Zhang N; May C; Hill M; Chung A
    Cancer Res; 1990 May; 50(10):3036-42. PubMed ID: 1692253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines.
    Fruehauf JP; Myers CE; Sinha BK
    J Natl Cancer Inst; 1990 Jul; 82(14):1206-9. PubMed ID: 2362291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution.
    Kim JH; Sherwood ER; Sutkowski DM; Lee C; Kozlowski JM
    J Urol; 1991 Jul; 146(1):171-6. PubMed ID: 2056586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor.
    Lantz M; Gullberg U; Nilsson E; Olsson I
    J Clin Invest; 1990 Nov; 86(5):1396-1402. PubMed ID: 2173717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptors for platelet derived growth factor in human glioma cell lines and influence of suramin on cell proliferation.
    Westphal M; Ackermann E; Hoppe J; Herrmann HD
    J Neurooncol; 1991 Dec; 11(3):207-13. PubMed ID: 1668406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells.
    Kopp R; Pfeiffer A
    Cancer Res; 1990 Oct; 50(20):6490-6. PubMed ID: 2170005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines.
    Totpal K; Aggarwal BB
    Cancer Res; 1991 Aug; 51(16):4266-70. PubMed ID: 1651157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of suramin, tumor necrosis factor and interferon gamma on human prostate carcinoma.
    Liu S; Ewing MW; Anglard P; Trahan E; La Rocca RV; Myers CE; Linehan WM
    J Urol; 1991 Feb; 145(2):389-92. PubMed ID: 1899122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
    Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
    Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor.
    Fujiuchi S; Ohsaki Y; Kikuchi K
    Oncology; 1997; 54(2):134-40. PubMed ID: 9075785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines.
    Favoni RE; Ravera F; Pirani P; Ardizzoni A; Noonan D; de Cupis A
    Eur J Pharmacol; 1994 Oct; 264(2):199-206. PubMed ID: 7851483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of lipopolysaccharide and IL-1 but not of TNF-induced activation of human endothelial cells by suramin.
    Strassmann G; Graber N; Goyert SM; Fong M; McCullers S; Rong GW; Beall LD
    J Immunol; 1994 Sep; 153(5):2239-47. PubMed ID: 7519646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.